Skip to Content
We are proud to announce that the 2025 edition of The Legal 500 United States has ranked Bleichmar Fonti & Auld LLP as a leading firm for Securities Litigation: Plaintiff. This prestigious recognition reflects the firm’s continued commitment to excellence, rigorous advocacy, and exceptional results on behalf of institutional investors and shareholders nationwide. The publication also highlights the firm’s expanding presence in Delaware corporate governance litigation and its ability to deliver victories in complex, high-stakes matters.
 
SECURITIES LITIGATION: PLAINTIFF
The Legal 500 reports Bleichmar Fonti & Auld LLP is widely praised for delivering ‘high-quality work expected of the largest securities fraud firms,’ while maintaining the efficiency and focus of a nimble, elite litigation boutique. The ‘tenacious and hardworking’ New York-based team has a strong track record in securities fraud class actions and shareholder derivative suits, with a notable ability to take cases from in-depth evaluation through trial and settlement.
 
Co-led by the ‘smart, thoughtful and aggressive’ Joseph Fonti and seasoned litigator Javier Bleichmar, the team achieved a landmark $420 million settlement for investors in the Teva Pharmaceuticals securities fraud class action. The firm also secured a historic $919 million recovery in a shareholder derivative action against the board of Tesla, Inc., a result that underscores its growing influence in Delaware litigation.
 
Key partners Nancy Kulesa, described as ‘outstanding’ by clients, and George Bauer were instrumental in the Tesla matter. Other key lawyers include Evan Kubota and Thayne Stoddard, who continue to strengthen the firm’s bench across complex securities and governance litigation.
 
We are grateful to our clients and peers for their trust and support, and to the Legal 500 researchers for recognizing our dedication and results-driven approach. We look forward to continuing our mission to protect shareholder rights and hold corporate wrongdoers accountable.

You may share a link to this page on any of the sites listed below or send link via email:

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Accept & Hide Message